Overview

Small companies are laser-focused on understanding biology and identifying a target therapeutic – but what happens once you have a lead compound? How can you effectively and efficiently manufacture your compound in a way that facilitates your pre-clinical and clinical development, as well as future development and commercial production?

A panel of experts will provide their insight on:

·         Key factors to consider when searching for a CMO

·         How to best facilitate technology transfer to your CMO while mitigating financial and production risks in this process

·         How to guarantee service levels, cost and commitment when contracting

·         Types of guarantees CMO’s are willing to provide

·         Red flags to look out for

·         Special issues related to complicated therapeutics (cell and gene therapy approaches)

*This program is part of BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA).

Agenda

11:00AM Opening Remarks

Allan Miranda | Regional Head, JLABS Canada

11:10AM Panel Discussion

Brent Stead | Specific Biologics

Mike Cooke | AmacaThera

Jana Machan | CCRM

Moderator: Mauricio Futran | Johnson & Johnson

11:55AM Audience Q&A

12:15PM End of Broadcast